Public recall detail

LEO 22811-S22 Proof of Concept Study (Phase II)

medium
Recall Safety notice
Quick summary

Quick summary: LEO 22811-S22 Proof of Concept Study (Phase II) .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: LEO 22811-S22 Proof of Concept Study (Phase II) .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Affected products

DescriptionLEO 22811-S22 Proof of Concept Study (Phase II) DIN, NPN, DIN-HIM N/A -Clinical Trial (IMP) Dosage form Oral Solution Strength Placebo of LEO 22811 Lot or serial number Bulk Batch No. 09 301 71 01 Secondary Packaging Code (Aptuit) CT 2673/1, CT 2673/4, CT2673/5 Companies Recalling Firm LEO Pharma 123 Commerce Valley Drive East, Suite 400, Thornhill, Ontario L3T 7W8 Marketing Authorization Holder N/A Recalling Firm LEO Pharma 123 Commerce Valley Drive East, Suite 400, Thornhill L3T 7W8 Ontario CANADA Marketing Authorization Holder LEO Pharma 123 Commerce Valley Drive East, Suite 400, Thornhill L3T 7W8 Ontario CANADA
Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Official source Monitor products Back to recalls

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...